Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.

In this case, we feel adjustment for multiple comparisons is not useful when presenting secondary outcomes or sensitivity analyses surrounding a single "main analysis." The secondary outcomes and sensitivity analyses are playing a supportive role to the main analysis, and generally provide the opportunity for greater caution in interpreting if the results are inconsistent between analyses, rather than an opportunity for declaring a result "significant" if any of the sensitivity analyses has a nominally significant p-value.

also in 7,732 other papers